Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 58

Similar articles for PubMed (Select 15170198)

1.

TORward AKTually useful mouse models.

Mellinghoff IK, Sawyers CL.

Nat Med. 2004 Jun;10(6):579-80. No abstract available.

PMID:
15170198
2.

Cancer: survival pathways meet their end.

McCormick F.

Nature. 2004 Mar 18;428(6980):267-9. No abstract available.

PMID:
15029179
3.

Molecular targeting: PI3 kinase pathway.

Dancey JE.

Ann Oncol. 2004;15 Suppl 4:iv233-9. Review. No abstract available.

4.
5.

Multiple signaling pathways promote B lymphocyte stimulator dependent B-cell growth and survival.

Woodland RT, Fox CJ, Schmidt MR, Hammerman PS, Opferman JT, Korsmeyer SJ, Hilbert DM, Thompson CB.

Blood. 2008 Jan 15;111(2):750-60. Epub 2007 Oct 17.

6.

Bcl-2 phosphorylation and apoptosis activated by damaged microtubules require mTOR and are regulated by Akt.

Asnaghi L, Calastretti A, Bevilacqua A, D'Agnano I, Gatti G, Canti G, Delia D, Capaccioli S, Nicolin A.

Oncogene. 2004 Jul 29;23(34):5781-91.

PMID:
15208671
7.

[16th EORTC-NCI-AACR symposium on new molecular targets and cancer therapeutics].

Lavelle F; EORTC-NCI-AACR.

Bull Cancer. 2004 Dec;91(12):985-8. French. No abstract available.

PMID:
15634640
8.

Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras.

Wislez M, Spencer ML, Izzo JG, Juroske DM, Balhara K, Cody DD, Price RE, Hittelman WN, Wistuba II, Kurie JM.

Cancer Res. 2005 Apr 15;65(8):3226-35.

9.

Constitutive activation of P I3 K-Akt and NF-kappaB during prostate cancer progression in autochthonous transgenic mouse model.

Shukla S, Maclennan GT, Marengo SR, Resnick MI, Gupta S.

Prostate. 2005 Aug 1;64(3):224-39.

PMID:
15712212
10.

Temsirolimus, an inhibitor of mammalian target of rapamycin.

Rini BI.

Clin Cancer Res. 2008 Mar 1;14(5):1286-90. doi: 10.1158/1078-0432.CCR-07-4719. Review. No abstract available.

12.

Cell signaling. Blocking Akt-ivity.

Restuccia DF, Hemmings BA.

Science. 2009 Aug 28;325(5944):1083-4. doi: 10.1126/science.1179972. No abstract available.

PMID:
19713516
13.

TOR signaling in mammals.

Carrera AC.

J Cell Sci. 2004 Sep 15;117(Pt 20):4615-6. No abstract available.

14.

Energy deregulation: licensing tumors to grow.

Garber K.

Science. 2006 May 26;312(5777):1158-9. No abstract available.

PMID:
16728625
15.

Functional proteomic analysis of a three-tier PKCepsilon-Akt-eNOS signaling module in cardiac protection.

Zhang J, Baines CP, Zong C, Cardwell EM, Wang G, Vondriska TM, Ping P.

Am J Physiol Heart Circ Physiol. 2005 Feb;288(2):H954-61. Epub 2004 Nov 4.

16.

A new mouse model of pancreatic cancer: PTEN gets its Akt together.

Maitra A, Hruban RH.

Cancer Cell. 2005 Sep;8(3):171-2.

17.

Physiological functions of protein kinase B/Akt.

Yang ZZ, Tschopp O, Baudry A, D├╝mmler B, Hynx D, Hemmings BA.

Biochem Soc Trans. 2004 Apr;32(Pt 2):350-4. Review.

PMID:
15046607
19.

Mammalian target of rapamycin (mTOR) inhibitors as anti-cancer agents.

Rao RD, Buckner JC, Sarkaria JN.

Curr Cancer Drug Targets. 2004 Dec;4(8):621-35. Review.

PMID:
15578919
20.

Rapamycin inhibits Akt-mediated oncogenic transformation and tumor growth.

Liu X, Powlas J, Shi Y, Oleksijew AX, Shoemaker AR, De Jong R, Oltersdorf T, Giranda VL, Luo Y.

Anticancer Res. 2004 Sep-Oct;24(5A):2697-704.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk